轉移性大腸直腸癌藥物市場－全球產業規模、佔有率、趨勢、機會及預測（按藥物類別、配銷通路、地區和競爭情況分類，2020-2030 年預測）

2024 年全球轉移性大腸直腸癌藥物市場價值為 34 億美元，預計在預測期內將穩定成長，到 2030 年的複合年成長率為 4.45%。全球轉移性大腸直腸癌藥物市場是更廣泛的腫瘤製藥行業中一個充滿活力且關鍵的領域。轉移性大腸直腸癌藥物 ​​(mCRC) 是一種毀滅性疾病，其特徵是癌細胞從結腸或直腸擴散到身體的其他部位，最常見的是肝臟和肺部。該市場致力於改善患者的治療效果和整體存活率，其特點是治療方法、診斷方法和治療劑的持續創新。該市場成長的主要驅動力之一是全球範圍內結直腸癌發病率的上升，特別是在人口老化的已開發國家。早期診斷和標靶治療、免疫療法和聯合治療的進步徹底改變了 mCRC 的管理，從而增加了對有效和個人化治療方案的需求。製藥公司處於該領域研發的前沿，投入大量資金進行臨床試驗和藥物研發，以推出療效更高、副作用更少的新療法。單株抗體、酪胺酸激酶抑制劑和免疫療法是治療 mCRC 方面取得突出進展的一些創新方法。

主要市場促進因素

大腸直腸癌發生率上升及人口老化

主要市場挑戰

晚期診斷

主要市場趨勢

免疫療法的進展

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：全球轉移性大腸直腸癌藥物市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依藥物類別（抗 EGFR（表皮生長因子受體）抑制劑、抗 VEGF（血管內皮生長因子）療法、抗 HER2（人類表皮生長因子受體 2）療法、免疫檢查點抑制劑、其他）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按藥物類別
  • 按配銷通路
  • 按地區

第5章：亞太地區轉移性大腸直腸癌藥物市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按藥物類別
  • 按配銷通路
  • 按國家
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第6章：歐洲轉移性大腸直腸癌藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第7章：北美轉移性大腸直腸癌藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲轉移性大腸直腸癌藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 9 章：中東和非洲轉移性大腸直腸癌藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 埃及

第10章：市場動態

• 驅動程式
• 挑戰

第 11 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 12 章：全球轉移性大腸直腸癌藥物市場：SWOT 分析

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Amgen Inc.
• EMD Serono
• Eli Lilly and company
• Genentech Inc.
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Sanofi SA
• Suzhou Zelgen Biopharmaceuticals
• Taiho Oncology

第 15 章：策略建議

第16章調查會社について,免責事項

Global Metastatic Colorectal Cancer Drugs Market was valued at USD 3.40 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.45% through 2030. The Global Metastatic Colorectal Cancer Drugs Market represents a dynamic and critical segment within the broader oncology pharmaceutical industry. Metastatic Colorectal Cancer Drugs (mCRC) is a devastating condition characterized by the spread of cancerous cells from the colon or rectum to other parts of the body, most commonly the liver and lungs. This market is marked by constant innovation in treatment approaches, diagnostic methods, and therapeutic agents, as it strives to improve patient outcomes and overall survival rates. One of the key drivers of growth in this market is the rising incidence of colorectal cancer worldwide, particularly in developed nations with aging populations. Early diagnosis and advancements in targeted therapies, immunotherapies, and combination treatments have revolutionized the management of mCRC, leading to increased demand for effective and personalized treatment options. Pharmaceutical companies are at the forefront of research and development in this space, investing heavily in clinical trials and drug discovery to introduce novel therapies with improved efficacy and fewer side effects. Monoclonal antibodies, tyrosine kinase inhibitors, and immunotherapies are some of the innovative approaches that have gained prominence in the treatment of mCRC.

Key Market Drivers

Rising Incidence of Colorectal Cancer & Aging Population

The rising global incidence of colorectal cancer (CRC) is a primary driver of the Global Metastatic Colorectal Cancer (mCRC) Drugs Market. In 2020, the global colorectal cancer burden was significant, with an estimated 1.9 million newly diagnosed cases and over 930,000 fatalities attributed to the disease. These figures underscore the increasing prevalence and mortality rate of colorectal cancer, highlighting the urgent demand for advanced treatment solutions and expanded healthcare interventions in both developed and emerging markets. As the number of diagnosed cases continues to escalate, the demand for advanced treatment options, innovative drug therapies, and improved patient care solutions is rising. This trend is creating significant business opportunities for pharmaceutical companies, biotech firms, and healthcare providers.

Key Market Challenges

Late-stage Diagnosis

Metastatic Colorectal Cancer Drugs begins as colorectal cancer but progresses to a stage where cancer cells have spread to other parts of the body, such as the liver, lungs, or distant lymph nodes. The problem often starts with late-stage diagnosis, where patients do not exhibit symptoms until the disease has already advanced.

Several factors contribute to the late-stage diagnosis of mCRC. One key factor is the lack of routine screening and awareness. Unlike breast or prostate cancer, colorectal cancer lacks widespread routine screening programs, leading to delayed detection. Moreover, some individuals may avoid seeking medical attention due to embarrassment or fear of invasive procedures associated with colorectal cancer screening. Healthcare disparities also play a role in late-stage diagnosis. Limited access to healthcare services, especially in underserved communities or low-income regions, can lead to delayed diagnosis and treatment initiation. Additionally, healthcare providers may not always consider colorectal cancer as a potential diagnosis, leading to misdiagnoses or delayed referrals to specialists.

Key Market Trends

Advancements in Immunotherapy

Advancements in immunotherapy have emerged as a potent force in the global Metastatic Colorectal Cancer Drugs (mCRC) market, ushering in a new era of hope and promise for patients facing this challenging disease. Immunotherapy, a groundbreaking treatment approach that harnesses the body's own immune system to target and destroy cancer cells, has begun to revolutionize the treatment landscape for mCRC.

Key immunotherapeutic agents, such as immune checkpoint inhibitors, have demonstrated remarkable efficacy in specific subsets of mCRC patients. Pembrolizumab and nivolumab, for instance, have gained FDA approval for mCRC patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. These therapies have shown the potential to induce long-lasting responses, providing new treatment options for a previously underserved patient population.

Key Market Players

• Amgen Inc.
• EMD Serono
• Eli Lilly and company
• Genentech Inc.
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Sanofi
• Suzhou Zelgen Biopharmaceuticals
• Taiho Oncology

Report Scope:

In this report, the Global Metastatic Colorectal Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metastatic Colorectal Cancer Drugs Market, By Drug Class:

• Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors
• Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
• Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
• Immune Checkpoint Inhibitors
• Others

Metastatic Colorectal Cancer Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Metastatic Colorectal Cancer Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metastatic Colorectal Cancer Drugs Market.

Available Customizations:

Global Metastatic Colorectal Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Metastatic Colorectal Cancer Drugs Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug Class (Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors, Anti-VEGF (Vascular Endothelial Growth Factor) Therapies, Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies, Immune Checkpoint Inhibitors, Others)
  • 4.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.3. By Region
  • 4.2.4. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Drug Class
  • 4.3.2. By Distribution Channel
  • 4.3.3. By Region

5. Asia Pacific Metastatic Colorectal Cancer Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class
  • 5.2.2. By Distribution Channel
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Metastatic Colorectal Cancer Drugs Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug Class
      • 5.3.1.2.2. By Distribution Channel
  • 5.3.2. India Metastatic Colorectal Cancer Drugs Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug Class
      • 5.3.2.2.2. By Distribution Channel
  • 5.3.3. Australia Metastatic Colorectal Cancer Drugs Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug Class
      • 5.3.3.2.2. By Distribution Channel
  • 5.3.4. Japan Metastatic Colorectal Cancer Drugs Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug Class
      • 5.3.4.2.2. By Distribution Channel
  • 5.3.5. South Korea Metastatic Colorectal Cancer Drugs Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug Class
      • 5.3.5.2.2. By Distribution Channel

6. Europe Metastatic Colorectal Cancer Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Metastatic Colorectal Cancer Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Germany Metastatic Colorectal Cancer Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Spain Metastatic Colorectal Cancer Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel
  • 6.3.4. Italy Metastatic Colorectal Cancer Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Class
      • 6.3.4.2.2. By Distribution Channel
  • 6.3.5. United Kingdom Metastatic Colorectal Cancer Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Class
      • 6.3.5.2.2. By Distribution Channel

7. North America Metastatic Colorectal Cancer Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Metastatic Colorectal Cancer Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Mexico Metastatic Colorectal Cancer Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. Canada Metastatic Colorectal Cancer Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel

8. South America Metastatic Colorectal Cancer Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Metastatic Colorectal Cancer Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. Argentina Metastatic Colorectal Cancer Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Colombia Metastatic Colorectal Cancer Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel

9. Middle East and Africa Metastatic Colorectal Cancer Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Metastatic Colorectal Cancer Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Saudi Arabia Metastatic Colorectal Cancer Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. UAE Metastatic Colorectal Cancer Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel
  • 9.3.4. Egypt Metastatic Colorectal Cancer Drugs Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Drug Class
      • 9.3.4.2.2. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Metastatic Colorectal Cancer Drugs Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Amgen Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. EMD Serono
• 14.3. Eli Lilly and company
• 14.4. Genentech Inc.
• 14.5. Novartis AG
• 14.6. Pfizer Inc.
• 14.7. F. Hoffmann-La Roche Ltd
• 14.8. Sanofi SA
• 14.9. Suzhou Zelgen Biopharmaceuticals
• 14.10. Taiho Oncology

15. Strategic Recommendations

16. About Us & Disclaimer